Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04592913
Title	Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	gastric adenocarcinoma gastroesophageal junction adenocarcinoma
Therapies	Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| ARG